A Study of LY2541546 in Women With Low Bone Mineral Density

Phase 2

Completed

• Conditions: Osteoporosis
• Interventions: Drug: LY2541546; Drug: Placebo

• Registration Number: NCT01144377
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The primary objectives of this study include evaluating the dose response of LY2541546 using bone mineral density (BMD) change from baseline as compared to placebo and evaluating the overall safety and tolerability of LY2541546 following multiple subcutaneous administrations in postmenopausal (PMP) women with low BMD. Following the last dose of study drug, participants will be able to participate in a 12 month extension to collect additional safety and efficacy data (no further treatment will be administered during this extension).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-06-11
• Study First Submitted QC: 2010-06-11
• Study First Posted: 2010-06-15
• Study Start: 2010-08
• Primary Completion: 2012-05
• Disposition First Submitted: 2012-09-18
• Disposition First Submitted QC: 2012-09-18
• Disposition First Posted: 2012-09-25
• Study Completion: 2013-02
• Results First Submitted: 2017-09-27
• Results First Submitted QC: 2017-10-28
• Results First Posted: 2017-12-04
• Status Verified: 2019-09
• Last Update Submitted: 2019-09-09
• Last Update Posted: 2019-09-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 154

Inclusion Criteria

• Ambulatory, postmenopausal women, inclusive.
• Have low bone mineral density (BMD), defined as a T-score or equivalent BMD absolute value (grams/square centimeter [g/cm^2]) for the lumbar spine of between -3.5 and -2.0, inclusive.
• Without language barrier, reliable, and willing to make themselves available for the duration of the study and to follow study procedures.
• Willing to take study drug and daily supplements (calcium and Vitamin D).
• Normal laboratory tests or laboratory test results determined not clinically significant by the investigator. Serum phosphate and serum calcium must be within normal limits, and platelet level greater than 100,000 cubic millimeters (mm^3).

Read More

Exclusion Criteria

• Have received treatment with any of the following medications more recently than 3 months prior to screening Androgen, Calcitonin, Estrogen (including over the counter preparations known to have estrogenic activity), Progestin (including over the counter preparations known to have progestogenic activity), selective estrogen receptor modulators (SERMs) (Raloxifene, Tamoxifen, Toremifene, Clomiphene), or Tibolone.
• Have previously used or currently use denosumab, parathyroid hormone (PTH) and/or PTH analogs, strontium ranelate, or parenteral formulations of bisphosphonates.
• Have received treatment with any oral bisphosphonate within the last year.
• Have received therapeutic doses of systemic corticosteroids for more than one month during the 6 months prior to screening.
• Have received therapeutic doses of fluorides (20 milligrams per day) for more than 3 months during the last 3 years, or for more than a total of 2 years, or any within the last 6 months.
• Have severe Vitamin D deficiency defined as 25-hydroxyvitamin D less than <9.2 nanograms per milliliter (ng/mL) [23 nanomoles per liter (nmol/L)] at screening. If the serum 25-hydroxy-vitamin D level at screening is less than or equal to 9.2 ng/mL and <20 ng/mL, participants will receive a loading dose of Vitamin D (at a dose of approximately 100,000 international units (IU) given orally) prior to enrollment.
• Have any known bone disorder other than low BMD or osteoporosis.
• Have a history of osteoporotic fractures, including known prevalent vertebral fracture or evidence of prevalent vertebral fracture on screening spine X-ray or dual-energy x-ray absorptiometry (DXA), or are considered to be at high risk for fracture.
• Presence of any abnormality (such as artifacts or osteophytes) that would confound DXA evaluation of lumbar vertebrae in the L-1 through L-4 region.
• Have a history of Bell's palsy, other cranial nerve disorders, or have a history of Temporomandibular Joint and Muscle Disorders (TMJDs).
• Have any history of cancer within the previous 5 years, except for excised superficial lesions such as basal cell carcinoma and squamous cell carcinoma of the skin.
• Have history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of constituting a risk when taking the study medication or of interfering with the interpretation of data.
• Have acute or chronic liver disease ([bilirubin >34 micromoles per liter (µmol/L) or >2.0 milligrams per deciliter (mg/dL), alanine transaminase [ALT/SGPT] >100 units per liter (U/L), or alkaline phosphatase >300 U/L)].
• Have impaired kidney function serum creatinine >135 µmol/L or >2.0 mg/dL.
• Have known allergy to LY2541546, any of diluents or excipients of LY2541546, or significant allergy to any other monoclonal antibody.
• History of excessive consumption of alcohol or abuse of drugs within the last year.
• Have poor medical condition or psychiatric risks for treatment with an investigational drug.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
180 mg LY2541546 Q2W	LY2541546	LY2541546: 180 milligrams (mg) administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
270 mg LY2541546 Q2W	LY2541546	LY2541546: 270 milligrams (mg) LY2541546 administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
270 mg LY2541546 Q12W + Placebo	Placebo	LY2541546: 270 milligrams (mg) administered subcutaneously every 12 weeks (Q12W) for 52 weeks. Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks.
180 mg LY2541546 Q4W + Placebo	LY2541546	LY2541546: 180 milligrams (mg) administered subcutaneously every 4 weeks (Q4W) for 52 weeks. Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks.
180 mg LY2541546 Q4W + Placebo	Placebo	LY2541546: 180 milligrams (mg) administered subcutaneously every 4 weeks (Q4W) for 52 weeks. Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks.
270 mg LY2541546 Q12W + Placebo	LY2541546	LY2541546: 270 milligrams (mg) administered subcutaneously every 12 weeks (Q12W) for 52 weeks. Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks.
Placebo Comparator Q2W	Placebo	Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.

Primary Outcome Measures

Name	Time	Method
Change From Baseline to 52 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD)	Baseline, 52 weeks	Lumbar spine bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA).; Least squares (LS) mean values were determined using a mixed-effects model repeated-measures (MMRM) analysis of covariance.; Factors in the model included treatment, time and the interaction of treatment by time as fixed effects, and baseline lumbar spine BMD as a covariate.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline to 12, 24, and 64 Weeks in Lumbar Spine Bone Mineral Density (BMD)	Baseline, 12 weeks and 24 weeks and 64 weeks	Lumbar spine bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA).; Least squares (LS) mean values were determined using a mixed-effects model repeated-measures (MMRM) analysis of covariance.; Factors in the model included treatment, time and the interaction of treatment by time as fixed effects, and baseline lumbar spine BMD as a covariate
Change From Baseline to 52 Week Endpoint in Bone-specific Alkaline Phosphatase (BSAP)	Baseline, 52 weeks
Change From Baseline to 24, 52, and 64 Weeks in Proximal Femur Bone Mineral Density (BMD)	Baseline, 24 weeks and 52 weeks and 64 weeks	Femoral neck and total hip bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA).; Least squares (LS) mean values were determined using a mixed-effects model repeated-measures (MMRM) analysis of covariance.; Factors in the model included treatment, time and the interaction of treatment by time as fixed effects, and baseline BMD as a covariate.
Change From Baseline to 52 Week Endpoint in Serum Type I Collagen Fragment (CTx)	Baseline, 52 weeks
Change From Baseline to 52 Week Endpoint in Osteocalcin	Baseline, 52 weeks
Change From Baseline to 52 Week Endpoint in Serum N-terminal Extension Propeptide of Type I Collagen (P1NP)	Baseline, 52 weeks
Change From Baseline to 52 Week Endpoint in Wrist Bone Mineral Density (BMD)	Baseline, 52 weeks	Total radius of the wrist bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA).; Least squares (LS) mean values were determined using a 1-factor analysis of covariance model with treatment group as the main effect and baseline BMD as a covariate.

Trial Locations

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.; 🇱🇹 Vilnius, Lithuania